IceCure Medical (Nasdaq: ICCM) back in compliance with bid price rule
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
IceCure Medical Ltd. reported that it has regained compliance with Nasdaq’s minimum bid price requirement. Nasdaq notified the company on June 18, 2026, after the closing bid price of IceCure’s ordinary shares was at least $1.00 per share for 10 consecutive business days from June 4 to June 17, 2026. With this, Nasdaq now considers the prior bid price deficiency matter closed, confirming the company’s continued listing under Nasdaq Listing Rule 5550(a)(2).
Positive
- IceCure Medical regained compliance with Nasdaq Listing Rule 5550(a)(2), confirming its shares met the $1.00 per share minimum bid price for 10 consecutive business days and closing the prior bid price deficiency matter.
Negative
- None.
Insights
IceCure removes immediate Nasdaq delisting risk by regaining minimum bid compliance.
IceCure Medical received confirmation from Nasdaq that it again meets the minimum bid price requirement in Listing Rule 5550(a)(2), which sets a $1.00 per share threshold. This followed 10 consecutive business days with a closing bid at or above that level.
This development closes the earlier bid price deficiency matter and supports the company’s continued listing on the Nasdaq Capital Market. Maintaining listing status helps keep access to U.S. capital markets and broader investor visibility, though future trading levels will still drive ongoing compliance.
Key Figures
Minimum bid price threshold: $1.00 per share
Compliance trading period: 10 consecutive business days
Nasdaq notice date: June 18, 2026
3 metrics
Minimum bid price threshold
$1.00 per share
Nasdaq Listing Rule 5550(a)(2) requirement
Compliance trading period
10 consecutive business days
Closing bid at or above $1.00 from June 4–17, 2026
Nasdaq notice date
June 18, 2026
Date Nasdaq informed IceCure it had regained compliance
Key Terms
Nasdaq Listing Rule 5550(a)(2), minimum bid price requirement, Report of Foreign Private Issuer, cryoablation, +1 more
5 terms
Nasdaq Listing Rule 5550(a)(2) regulatory
"the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2)"
minimum bid price requirement regulatory
"regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2)"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
Report of Foreign Private Issuer regulatory
"Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16"
A report of a foreign private issuer is a formal filing that a non‑U.S. company makes to U.S. regulators to share important business, financial, or governance information with American investors. Think of it as a regular update or press packet that keeps investors informed about events that could change a company’s value—like earnings, management changes, contracts, or regulatory developments—so investors can make timely, informed decisions.
cryoablation medical
"developer of minimally-invasive cryoablation technology that destroys tumors by freezing"
A medical treatment that uses extreme cold to freeze and destroy unwanted tissue, such as small tumors or heart tissue causing irregular rhythms; think of it like applying a focused freezer to stop a problem spot without cutting it out. It matters to investors because devices, tools, and drugs tied to cryoablation, plus clinical results, approval status and insurance coverage, can drive sales, shape market adoption and affect the financial outlook of healthcare companies.
Form 6-K regulatory
"this Report of Foreign Private Issuer on Form 6-K"
A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.
FAQ
What did IceCure Medical (ICCM) announce in its June 2026 Form 6-K?
IceCure Medical announced that Nasdaq confirmed the company has regained compliance with its minimum bid price requirement. This followed 10 consecutive business days where IceCure’s closing bid price met or exceeded $1.00 per share, closing the prior deficiency matter.
How did IceCure Medical regain compliance with Nasdaq’s minimum bid price rule?
IceCure Medical regained compliance after its ordinary shares closed at $1.00 per share or higher for 10 consecutive business days. Nasdaq reviewed this trading history from June 4 to June 17, 2026, and then issued a written notice of compliance on June 18, 2026.
Which Nasdaq rule now considers IceCure Medical back in compliance?
IceCure Medical is back in compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. Nasdaq determined compliance after the company’s shares met this threshold for 10 consecutive business days in June 2026.
When did Nasdaq notify IceCure Medical about regaining bid price compliance?
Nasdaq notified IceCure Medical on June 18, 2026, that it had regained compliance with the minimum bid price requirement. The decision followed a review of trading from June 4 through June 17, during which the closing bid price met the $1.00 per share threshold.